Lower Prevalence of Osteoporosis in Patients with COPD Taking Anti-Inflammatory Compounds for the Treatment of Diabetes: Results from COSYCONET

Lower Prevalence of Osteoporosis in Patients with COPD Taking Anti-Inflammatory Compounds for the Treatment of Diabetes: Results from COSYCONET

Kathrin Kahnert,1 Rudolf A Jörres,2 Tanja Lucke,2 Franziska C Trudzinski,3 Pontus Mertsch,1 Christiane Bickert,1 Joachim H Ficker,4 Jürgen Behr,1 Robert Bals,5 Henrik Watz,6 Tobias Welte,7 Claus F Vogelmeier,8 Peter Alter8 On behalf of COSYCONET Study Group1Department of Medicine V, University Hospi...

Full description

Bibliographic Details
Main Authors:	Kahnert K, Jörres RA, Lucke T, Trudzinski FC, Mertsch P, Bickert C, Ficker JH, Behr J, Bals R, Watz H, Welte T, Vogelmeier CF, Alter P
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-11-01
Series:	International Journal of COPD
Subjects:	chronic obstructive pulmonary disease oral corticosteroids inhaled corticosteroids anti-inflammatory metformin diabetes
Online Access:	https://www.dovepress.com/lower-prevalence-of-osteoporosis-in-patients-with-copd-taking-anti-inf-peer-reviewed-fulltext-article-COPD

Similar Items

Adherence To Respiratory And Nonrespiratory Medication In Patients With COPD: Results Of The German COSYCONET Cohort
by: Königsdorfer N, et al.
Published: (2019-10-01)

Disease Progression and Age as Factors Underlying Multimorbidity in Patients with COPD: Results from COSYCONET
by: Alter P, et al.
Published: (2022-07-01)

Basic Determinants of Disease Knowledge in COPD Patients: Results from COSYCONET
by: Fischer C, et al.
Published: (2022-07-01)

Unravelling the Information Contained in the Single Items of the COPD Assessment Test for Different Outcomes and Smoking Status in Patients with COPD: Results from COSYCONET
by: Alter P, et al.
Published: (2024-12-01)

Impact of Education on COPD Severity and All-Cause Mortality in Lifetime Never-Smokers and Longtime Ex-Smokers: Results of the COSYCONET Cohort
by: Lutter JI, et al.
Published: (2020-11-01)

Characteristics of Current Smokers versus Former Smokers with COPD and Their Associations with Smoking Cessation Within 4.5 Years: Results from COSYCONET
by: Alter P, et al.
Published: (2023-12-01)

Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort
by: Greulich T, et al.
Published: (2018-09-01)

Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population
by: Vestbo J, et al.
Published: (2019-04-01)

Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort
by: Alter P, et al.
Published: (2019-09-01)

Inhaled corticosteroids can reduce osteoporosis in female patients with COPD
by: Liu SF, et al.
Published: (2016-07-01)

The risk of osteoporosis in patients with asthma
by: Indumathi Kumarathas, et al.
Published: (2020-01-01)

Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis
by: Cheng SL
Published: (2018-09-01)

Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts
by: Cheng SL, et al.
Published: (2016-09-01)

Clinical factors linked to the type of respiratory medication in COPD: results from the COSYCONET cohort
by: Peter Alter, et al.
Published: (2023-11-01)

Associated Factors of Pneumonia in Individuals with Chronic Obstructive Pulmonary Disease (COPD) Apart from the Use of Inhaled Corticosteroids
by: Rosario Lineros, et al.
Published: (2023-04-01)

Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies
by: Lodise TP, et al.
Published: (2020-11-01)

Effects of Fluticasone Propionate on Klebsiella pneumoniae and Gram-Negative Bacteria Associated with Chronic Airway Disease
by: Lesa A. Begley, et al.
Published: (2022-12-01)

Systemic Adverse Events Associated with Locally Administered Corticosteroids
by: Femke De Vleeschhauwer, et al.
Published: (2024-08-01)

Impact of the COVID-19 pandemic on the behaviour and health status of patients with COPD: results from the German COPD cohort COSYCONET
by: Kathrin Kahnert, et al.
Published: (2021-08-01)

Risk of pneumonia with budesonide-containing treatments in COPD: an individual patient-level pooled analysis of interventional studies
by: Hollis S, et al.
Published: (2017-04-01)

Inhaled Corticosteroids and the Lung Microbiome in COPD
by: Holly R. Keir, et al.
Published: (2021-09-01)

Response to high-altitude triggers in seasonal asthmatics on and off inhaled corticosteroid treatment
by: Pontus Mertsch, MD, et al.
Published: (2022-10-01)

Medication Adherence in Children with Asthma
by: McCrossan P, et al.
Published: (2024-03-01)

Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS
by: Bafadhel M, et al.
Published: (2022-12-01)

Effects of triple therapy on disease burden in patients of GOLD groups C and D: results from the observational COPD cohort COSYCONET
by: Jennifer A. Zader, et al.
Published: (2024-03-01)

Prediction of lung emphysema in COPD by spirometry and clinical symptoms: results from COSYCONET
by: Christina Kellerer, et al.
Published: (2021-09-01)

Regional variation in intensity of inhaled asthma medication and oral corticosteroid use in Denmark, Finland, and Sweden
by: Lauri Lehtimäki, et al.
Published: (2022-12-01)

Corticosteroids in the treatment of acute asthma
by: Abdullah A Alangari
Published: (2014-01-01)

The Impact of Inhaled Corticosteroids on the Prognosis of Chronic Obstructive Pulmonary Disease
by: Park JW, et al.
Published: (2023-05-01)

Inhaled Corticosteroids Is Not Associated with the Risk of Pneumonia in Asthma
by: Ye Jin Lee, et al.
Published: (2023-07-01)

Is underuse of Inhaled Corticosteroids for Asthma in India contributing to 42% of global asthma deaths?
by: Sundeep Salvi, et al.
Published: (2022-01-01)

Chronic obstructive pulmonary disease lost in translation: Why are the inhaled corticosteroids skeptics refusing to go?
by: Faisal A AI-Kassimi, et al.
Published: (2013-01-01)

Inhaled budesonide for adults with mild-to-moderate asthma: a randomized placebo-controlled, double-blind clinical trial
by: Ana Luisa Godoy Fernandes, et al.
Published: (2001-09-01)

Expiratory Venous Volume and Arterial Tortuosity are Associated with Disease Severity and Mortality Risk in Patients with COPD: Results from COSYCONET
by: Stoleriu MG, et al.
Published: (2024-07-01)

Characterization of COPD Admissions During the First COVID-19 Outbreak
by: Cosio BG, et al.
Published: (2021-06-01)

Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study
by: Sarah Marietta von Siemens, et al.
Published: (2019-02-01)

Evaluation of adherence to guideline-directed therapy and risk factors for exacerbation in mild asthma: a retrospective chart review
by: Beth A. Zerr, et al.
Published: (2024-03-01)

Association of Patients’ Knowledge on the Disease and Its Management with Indicators of Disease Severity and Individual Characteristics in Patients with Chronic Obstructive Pulmonary Disease (COPD): Results from COSYCONET 2
by: Fischer C, et al.
Published: (2024-12-01)

The Role of Dual Bronchodilation and the Conscientious Use of Inhaled Corticosteroid in COPD
by: Ricardo G. Figueiredo, et al.
Published: (2022-08-01)

Inhaled Corticosteroids in COPD: Trying to Make a Long Story Short
by: Tantucci C, et al.
Published: (2020-04-01)